Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Featured trial
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

aplastic anemia
anemia
myelodysplastic syndrome (mds)
anemia studies
myelodysplastic syndromes
  • 172 views
  • 22 Dec, 2020
  • 1 location
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

This randomised controlled trial will determine the non-inferiority of stopping empiric antibiotics prior to absolute neutrophil count (ANC) recovery (Early Stopping) versus stopping antibiotics

  • 0 views
  • 12 Dec, 2021
  • 1 location
Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection (FRANCiS-NF)

This is a comparative study for adult participants with cancer who are suspected to have neutropenic fever (or fever with low neutrophil count) in emergency department. Neutrophil is a kind of

  • 0 views
  • 11 Jul, 2022
  • 1 location
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)

ULN absolute neutrophil count (ANC) ≥ 1,500 cells/µL platelet count ≥ 100,000/µL hemoglobin ≥ 9.0 g/dL Subjects who have at least a

metastatic pancreatic ductal adenocarcinoma
aptt
fluorouracil
pancreatic ductal adenocarcinoma
leucovorin
  • 1 views
  • 29 Jun, 2022
  • 1 location
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells …

  • 61 views
  • 01 Oct, 2023
  • 108 locations
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts …

erbb2
cancer chemotherapy
HER2
osimertinib
EGFR
  • 320 views
  • 09 Mar, 2022
  • 51 locations
Improving White Blood Cell Collection From Healthy Donors

Background White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells. Transfusions of these cells can help improve the body's ability to fight infection. However, most of the cells are located in the …

Accepts healthy volunteers
  • 41 views
  • 30 Sep, 2023
  • 1 location
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflammation of the mouth or gut) and infection. This study has two cohorts. The first cohort is subjects

fludarabine
ejection fraction
cell transplantation
melphalan
myeloid leukemia
  • 42 views
  • 26 May, 2022
  • 1 location
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplantation

absolute neutrophil count and platelets. To evaluate the incidence of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and other infections occurring during the 100 days post-transplant.

  • 0 views
  • 09 Apr, 2023
  • 1 location
Folinic Acid for Prevention of Pemetrexed-induced Toxicity (FLEX)

between treatment groups in neutrophil count (*109/L) at day 8-10 after administration of pemetrexed (nadir). Secondary endpoints The grade neutropenia (according to the CTCAE version 5, 2017) at

  • 0 views
  • 28 Aug, 2023
  • 1 location